Activation of Stress-activated MAP Protein Kinases Up-regulates Expression of Transgenes Driven by the Cytomegalovirus Immediate/early Promoter
Overview
Authors
Affiliations
The immediate/early promoter/enhancer of cytomegalovirus (CMV promoter) is one of the most commonly used promoters for expression of transgenes in eukaryotic cells. In practice, the CMV promoter is often thought of as a constitutively active unregulated promoter. However, we have observed that transcription from the CMV promoter can be up-regulated by a variety of environmental stresses. Many forms of cellular stress stimulate MAP kinase signalling pathways, resulting in activation of stress-activated protein kinases [SAPKs, also called Jun N-terminal kinases (JNKs)] and p38 kinases. We have found that the same conditions that lead to activation of SAPK/JNKs and p38 kinases can also dramatically increase expression from the CMV promoter. Inhibitors of p38 kinases abolished basal transcription from the CMV promoter and completely blocked stress-induced up-regulation of the CMV promoter. Overexpression of a dominant negative JNK kinase had no effect on basal transcription, but significantly reduced up-regulation caused by stress. These results have grave implications for use of the CMV promoter. If the CMV promoter can be up-regulated by cellular stresses, inadvertent activation of the stress kinase pathways may complicate, if not invalidate, the interpretation of a wide range of experiments.
Thampi P, Seabaugh K, Pezzanite L, Chu C, Phillips J, Grieger J Gene Ther. 2023; 30(12):792-800.
PMID: 37696981 PMC: 10727982. DOI: 10.1038/s41434-023-00420-2.
Skandorff I, Gille J, Ragonnaud E, Andersson A, Schrodel S, Thirion C Viruses. 2023; 15(8).
PMID: 37632028 PMC: 10458386. DOI: 10.3390/v15081686.
Cell factory engineering: Challenges and opportunities for synthetic biology applications.
Bachhav B, de Rossi J, Llanos C, Segatori L Biotechnol Bioeng. 2023; 120(9):2441-2459.
PMID: 36859509 PMC: 10440303. DOI: 10.1002/bit.28365.
Gene therapy approaches for equine osteoarthritis.
Thampi P, Samulski R, Grieger J, Phillips J, McIlwraith C, Goodrich L Front Vet Sci. 2022; 9:962898.
PMID: 36246316 PMC: 9558289. DOI: 10.3389/fvets.2022.962898.
De Backer J, Lin A, Vanden Berghe W, Bogaerts A, Hoogewijs D Redox Biol. 2022; 55:102399.
PMID: 35850009 PMC: 9294208. DOI: 10.1016/j.redox.2022.102399.